Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis

References

• Dye C, Floyd K, Uplekar M. WHO report. World Health Organization; Geneva, 2008.
   Google Scholar
• Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, Hashimoto S, Inoue Y, Sakatani M, Kobayashi E, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191-1204; PMID:16216394; http://dx.doi.org/10.1016/j.vaccine.2005.08.103
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, McMurray DN, Dela Cruz EC, Tan EV, Gelber R, et al. Evaluation of a novel vaccine (HVJ-liposome/ HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomologus monkey model of TB. Vaccine 2007; 25(16):2990-3; PMID:17280753; http://dx.doi.org/10.1016/j.vaccine.2007.01.014
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y. Tuberculosis vaccine development; The development of novel (preclinical) DNA vaccine. Human Vaccines 2010; 6(4):297-308; PMID:20372079; http://dx.doi.org/10.4161/hv.6.4.10172
   PubMed Web of Science ®Google Scholar
• Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, Muraki Y, Kanamaru N, Hashimoto S, Takai H, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-2135; PMID:15755583; http://dx.doi.org/10.1016/j.vaccine.2005.01.057
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6:219-226; PMID:12161188; http://dx.doi.org/10.1006/mthe.2002.0647
   PubMed Web of Science ®Google Scholar
• Mima H, Yamamoto S, Ito M, Tomoshige R, Tabata Y, Tamai K, Kaneda Y. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector. Mol Cancer Ther 2006; 5:1021-1028; PMID:16648574; http://dx.doi.org/10.1158/1535-7163.MCT-05-0352
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol 2011; 2011:Article ID:549281; http://dx.doi.org/10.1155/2011/549281
   Google Scholar
• Okada M Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, McMurray DN, Dela Cruz EC, Tan EV, Saunderson P, et al. Novel prophylactic and therapeutic vaccine against tuberculosis. Vaccine 2009; 27:3267-70; PMID:19200841; http://dx.doi.org/10.1016/j.vaccine.2009.01.064
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, et al. Novel therapeutic vaccine: Granulysin and new DNA vaccine against Tuberculosis. Human Vaccines 2011; 7:60-7; PMID:21546794; http://dx.doi.org/10.4161/hv.7.0.14563
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Nakajima T, Hashimoto S, Nakatani H, Nishimatsu S, Nishida Y, Kanamaru N, Kaneda Y, Takamori Y, et al. The study of novel DNA vaccines against tuberculosis: Induction of pathogen-specific CTL in the mouse and monkey models of tuberculosis. Human Vaccines and Immunotherapeutics 2013; 9(3):515-25; PMID:23249543; http://dx.doi.org/10.4161/hv.23229
   PubMed Web of Science ®Google Scholar
• Kita Y, Okada M, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, et al. Development of therapeutic and prophylactic vaccine against tuberculosis using monkey and granulysin transgenic mice models. Human Vaccines 2011; 7:108-14; PMID:21263229; http://dx.doi.org/10.4161/hv.7.0.14571
   PubMed Web of Science ®Google Scholar
• Huygen K. DNA vaccines: application to tuberculosis. Int J Tuberc Lung Dis 1998; 2(12):971-8; PMID:9869111
   PubMed Web of Science ®Google Scholar
• Lowrie DB. DNA vaccines against tuberculosis. Curr Opin Mol Ther 1999; 1(1):30-3; PMID:11249680
   PubMedGoogle Scholar
• Hoft D. Tuberculosis vaccine development:goals, immunological design, and evaluation. Lancet 2008; 372:164-75
   PubMed Web of Science ®Google Scholar
• Gupta UD, Katoch VM, McMurray DN. Current status of TB vaccines. Vaccine 2007; 25:3742-51; PMID:17321015; http://dx.doi.org/10.1016/j.vaccine.2007.01.112
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93-129; PMID:11244032; http://dx.doi.org/10.1146/annurev.immunol.19.1.93
   PubMed Web of Science ®Google Scholar
• Rook G.A.W, Lowrie D.B., Hernandez-Pando R. Immunotherapeutics for Tuberculosis on experimental animals: Is there a common pathway activated by effective protocols? J Inf Dis 2007; 196:191–198; http://dx.doi.org/10.1086/518937
   PubMed Web of Science ®Google Scholar
• Kaufmann S.H.E, Lange C, Rao M, Balaji KN, Lotze M, Schito M, Zumla AI, Maeurer M. Progress in tuberculosis vaccine development and host-directed therapies–a state of the art review. Lancet Respir Med 2014; 2(4):301-20; PMID:24717627; http://dx.doi.org/10.1016/S2213-2600(14)70033-5
   PubMed Web of Science ®Google Scholar
• Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ. The Philippine cynomolgus monkey provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2(4):430-6; PMID:8597953; http://dx.doi.org/10.1038/nm0496-430
   PubMed Web of Science ®Google Scholar
• Kita Y, Hashimoto S, Nakajima T, Nakatani H, Nishimatsu S, Nishida Y, Kanamaru N, Kaneda Y, Takamori Y, McMurray D, et al. Novel therapeutic vaccines [(Hsp65+IL-12)DNA-, granulysin- and Ksp37-vaccine] against tuberculosis and synergistic effects in the combination with chemotherapy., Human Vaccines and immunotherapeutics 2013; 9(3):526-33; http://dx.doi.org/10.4161/hv.23230
   PubMed Web of Science ®Google Scholar
• Global tuberculosis control-surveillance, planning, financing. Geneva, World Health Organization, 2014.
   Google Scholar
• Okada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, Peiris JS, Chen PJ, Yamamoto N, Tashiro M, et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models. Vaccine 2007; 25:3038-3040; PMID:17289225; http://dx.doi.org/10.1016/j.vaccine.2007.01.032
   PubMed Web of Science ®Google Scholar
• Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93-129; PMID:11244032; http://dx.doi.org/10.1146/annurev.immunol.19.1.93
   PubMed Web of Science ®Google Scholar
• Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, et al. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med 2013; 88(4):492-502; http://dx.doi.org/10.1164/rccm.201208-1385OC
   Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381(9871):1021-8; PMID:23391465; http://dx.doi.org/10.1016/S0140-6736(13)60177-4
   PubMed Web of Science ®Google Scholar
• Kagina BM, Tameris MD, Geldenhuys H, Hatherill M, Abel B, Hussey GD, Scriba TJ, Mahomed H, Sadoff JC, Hanekom WA, et al.: The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses. Vaccine 2014; 32(45):5908-17; PMID:25218194; http://dx.doi.org/10.1016/j.vaccine.2014.09.001
   PubMed Web of Science ®Google Scholar
• Zumla A, Memish ZA, Maeurer M, Bates M, Mwaba P, Al-Tawfi q, Denning DW, Hayden HG, Hui DS. Emerging novel and antimicrobial- resistant respiratory treat infections: new drug development and therapeutic options. Lancet Infect Dis 2014; 14:1136-49; PMID:25189352; http://dx.doi.org/10.1016/S1473-3099(14)70828-X
   PubMed Web of Science ®Google Scholar
• Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscolla M, Rothe T, Hömke R, Ritter C, et al. Acquired resistance to bedaquiline to delamanid in therapy for tuberculosis. N Eng. J. Med 2015; 373(20):1986-1988; http://dx.doi.org/10.1056/NEJMc1505196
   PubMed Web of Science ®Google Scholar
• Tadolini M, Lingtsang RD Tiberi S Enwerem M D'Ambrosio L Sadutshang TD Centis R Migliori GB. First case of extensively drug-resistant tuberculosis treated with both delamanidand bedaquiline. The European Respiratory Society 2016 Jun 10; Pii:ERJ-00637-2016.
   Google Scholar
• Hoffmann H, Kohl TA, Hofmann-Thiel S, Merker M, Beckert P, Jaton K, Nedialkova L, Sahalchyk E, Rothe T, Keller PM, et al. Delamanid and Bedaquiline Resistance in Mycobacterium tuberculosis Ancestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee. Am J Respir Crit Care Med 2016; 193(3):337-40; PMID:26829425; http://dx.doi.org/10.1164/rccm.201502-0372LE
   PubMed Web of Science ®Google Scholar
• Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci U S A 1981; 78(12):7717-21; PMID:6801660; http://dx.doi.org/10.1073/pnas.78.12.7717
   PubMed Web of Science ®Google Scholar
• Okada M, Kita Y, Kanamaru N, Hashimoto S, Uchiyama Y, Mihara M, Inoue Y, Ohsugi Y, Kishimoto T, Sakatani M. Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-α antibody in mice. Clin Dev Immunol 2011; 2011: Article ID: 404929; http://dx.doi.org/10.1155/2011/404929
   Google Scholar